HeartBeam (BEAT)
NASDAQ:BEAT
BEAT Stock Chart & Stats
$2.56
$0.00(0.00%)
At close: 4:00 PM EST
$2.56
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.54 - $4.00
Previous CloseN/A
Volume12.23K
Average Volume (3M)89.04K
Market Cap
$47.25M
Enterprise Value$35.23M
Total Cash (Recent Filing)$4.38M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.78
Next Earnings
May 07, 2026EPS Estimate
-0.14Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.14
Shares Outstanding41,087,870
10 Day Avg. Volume76,817
30 Day Avg. Volume89,039
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)31.08
Price to Sales (P/S)0.00
P/FCF Ratio-5.55
Enterprise Value/Market Cap0.75
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.67
Forecast
1Y Price Target
$4.50Price Target Upside75.78% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.52
Revenue Forecast (FY)$2.09M
Bulls Say, Bears Say
Bulls Say
Regulatory De‑risking — FDA ClearancesSecuring multiple 510(k) clearances and a rapid overturn of an NSE materially reduces regulatory risk for core software, supports faster commercialization pathways and gives partners/customers confidence. This durable de‑risking aids adoption, clinical studies, and payer conversations over coming quarters.
Product Technical Progress — 12‑lead Patch PrototypeA functioning 12‑lead patch prototype demonstrates technical feasibility of a differentiated product combining continuous monitoring with instant 12‑lead capture. If clinical studies confirm performance, this creates a durable product advantage enabling new use cases, differentiation versus incumbent monitors, and a scalable device platform.
Strategic AI And Clinical PartnershipsLeadership with demonstrated AI expertise plus a Mount Sinai collaboration builds a sustainable competitive edge: clinically annotated data, algorithm development, and credibility. These assets support differentiated diagnostic capabilities, accelerate regulatory/clinical validation, and strengthen long‑term product defensibility.
Bears Say
No Revenue And Large Net LossesAbsence of revenue and persistent, sizable losses mean product‑market fit is unproven and operational sustainability depends wholly on external funding. Over a 2–6 month horizon this reduces strategic flexibility, increases dilution risk, and limits the company's ability to scale clinical programs or commercial efforts without new capital.
Material Near‑term Funding ShortfallA large funding gap relative to cash on hand creates immediate execution risk: management must secure capital, which can dilute shareholders, slow pivotal trials, or force cuts. This structural financing constraint directly threatens planned regulatory and commercial timelines across the next several quarters.
Concentrated Go‑to‑market And Reimbursement UncertaintyRelying on a small, premium concierge segment limits near‑term scale and revenue visibility. Longer‑term growth depends on reimbursement and broader adoption, both uncertain and contingent on pivotal clinical results. This constrains sustainable margin expansion and increases commercialization execution risk.
HeartBeam News
BEAT FAQ
What was HeartBeam’s price range in the past 12 months?
HeartBeam lowest stock price was $0.54 and its highest was $4.00 in the past 12 months.
What is HeartBeam’s market cap?
HeartBeam’s market cap is $47.25M.
When is HeartBeam’s upcoming earnings report date?
HeartBeam’s upcoming earnings report date is May 07, 2026 which is in 25 days.
How were HeartBeam’s earnings last quarter?
HeartBeam released its earnings results on Mar 12, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.138 by -$0.002.
Is HeartBeam overvalued?
According to Wall Street analysts HeartBeam’s price is currently Undervalued.
Does HeartBeam pay dividends?
HeartBeam does not currently pay dividends.
What is HeartBeam’s EPS estimate?
HeartBeam’s EPS estimate is -0.14.
How many shares outstanding does HeartBeam have?
HeartBeam has 41,087,870 shares outstanding.
What happened to HeartBeam’s price movement after its last earnings report?
HeartBeam reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.138. Following the earnings report the stock price went down -7.483%.
Which hedge fund is a major shareholder of HeartBeam?
Currently, no hedge funds are holding shares in BEAT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeartBeam Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$4.50 (75.78% Upside)
$4.50 (75.78% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-22.97%
12-Months-Change
Fundamentals
Return on Equity
-571.06%
Trailing 12-Months
Asset Growth
78.36%
Trailing 12-Months
Company Description
HeartBeam
HeartBeam, Inc., a medical technology company, primarily focuses on telemedicine solutions for the detection and monitoring of cardiac disease outside a healthcare facility setting. The company also focuses on providing diagnostic data to physicians with care management of patients with cardiovascular disease. Its telehealth product comprises a credit card sized electrocardiogram machine and a cloud-based diagnostic software system to address the rapidly growing field of remote patient monitoring. The company was incorporated in 2015 and is headquartered in Santa Clara, California.
BEAT Company Deck
BEAT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call conveyed meaningful de‑risking of the underlying technology (two FDA 510(k) clearances, working patch prototype, ALIGN ACS pilot enrollment, AI collaboration with Mount Sinai, and an initial commercial partner) and a disciplined cost posture. However, these operational and clinical achievements are balanced by material near‑term financial risk (only $4.4M cash on hand vs. projected $17M–$19M burn in 2026), uncertain regulatory pathway for the ACS indication, and the need to validate commercial adoption beyond a small concierge initial market. Overall, the company demonstrated strong technical and strategic progress but faces significant execution and funding risks that temper the outlook.View all BEAT earnings summariesBEAT Stock 12 Month Forecast
Average Price Target
$4.50
▲(75.78% Upside)
Technical Analysis
Ownership Overview
11.57% Insiders
2.87% Mutual Funds
2.15% Other Institutional Investors
80.70% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---